Olokizumab vs placebo or usual care
WHO progression score (level 7 or above) D28 ‐ not reported · people with mild/moderate/severe/critical COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
- Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found